摘要
由于分枝杆菌结核病家族对于传统治疗方法的阻力越来越大,防治结核病变得越来越难。因此,我们需要分离出新的药物靶点,并且随后设计出该药品的特效抑制剂。在细菌、藻类、植物和真菌中、支链氨基酸(BCAA)的合成是由乙酰羟酸合成酶(AHAS)酶组催化完成的。细菌AHAS利用辅酶因子如二磷酸硫胺(ThDP),黄素腺嘌呤二核苷酸(FAD)和二价金属阳离子(通常是镁离子)等,来催化异亮氨酸、亮氨酸和缬氨酸的生物合成。该酶的合成代谢形式现在正在讨论中。其形式被认为事实上包括两个亚单位,一个起催化作用,一个起调节作用。该酶催化反应的产物分别是由丙酮酸盐自缩合或由丙酮酸盐和2-丁酮酸缩合获得的2-乙酰乳酸盐或2-乙酰-2-羟基丁酸盐。这些产物会被一系列其他酶转化为BCAA。AHAS催化的阶段是整个流程的开始,然后该阶段可以被该途径的抑制途径选择性地针对。被编码为 ilvB 和 ilvN 操纵子的分枝杆菌结核病AHAS在结构上与大肠杆菌AHAS相关,且功能相似。因此,属于磺脲类,咪唑啉酮类和苯甲酰酯的特效药可作为分枝杆菌结核病AHAS抑制剂,这些抑制剂最终会耗尽细菌的BCAA供给,从而高效抑菌。
关键词: 乙酰羟酸合成酶,AHAS抑制剂,苯甲酰酯,支链氨基酸,咪唑啉酮,磺脲。
图形摘要
Current Drug Targets
Title:Mechanisms of bacterial acetohydroxyacid synthase (ahas) and specific inhibitors of Mycobacterium tuberculosis ahas as potential drug candidates against tuberculosis
Volume: 16 Issue: 7
Author(s): Kunal Gokhale and Bhargav Tilak
Affiliation:
关键词: 乙酰羟酸合成酶,AHAS抑制剂,苯甲酰酯,支链氨基酸,咪唑啉酮,磺脲。
摘要: On account of the ever increasing resistance of M.tuberculosis strains to orthodox therapy regimens, the task of combating tuberculosis becomes even more challenging. Therefore, there arises a need to isolate new drug targets and subsequently design specific inhibitors for the same. In bacteria, algae, plants and fungi, the synthesis of Branched Chain Amino Acids (BCAAs) is catalyzed by Acetohydroxyacid Synthases (AHAS) group of enzymes. Bacterial AHAS (EC 2.2.1.6) catalyzes the biosynthesis of isoleucine, leucine and valine by utilizing cofactors like Thiamin Diphosphate (ThDP), Flavin Adenine Dinucleotide (FAD) and a divalent metal cation (Usually Mg2+). The anabolic form of the enzyme which is presently under discussion consists of two subunits out of which one is catalytic while the other is regulatory in nature. The product of this enzyme catalyzed reaction is either 2-acetolactate or 2-aceto-2-hydroxybutyrate obtained from self-condensation of pyruvate or condensation of puruvate and 2-ketobutyrate, respectively. These are further converted to the BCAAs by a series of other enzymes. The step catalyzed by AHAS is the first in the entire cascade and hence can be selectively targeted for the inhibition of this pathway. M.tuberculosis AHAS, which is encoded by the ilvB and ilvN operons is structurally related to E.coli AHAS and has a similar function. Therefore, specific drugs belonging to the classes of sulfonylureas, imidazolinones and benzoyl esters can be used as inhibitors of M.tuberculosis AHAS which would consequently deplete the BCAA supply to the bacteria. Thus, efficient bacteriostasis can be achieved.
Export Options
About this article
Cite this article as:
Kunal Gokhale and Bhargav Tilak , Mechanisms of bacterial acetohydroxyacid synthase (ahas) and specific inhibitors of Mycobacterium tuberculosis ahas as potential drug candidates against tuberculosis, Current Drug Targets 2015; 16 (7) . https://dx.doi.org/10.2174/1389450116666150416115547
DOI https://dx.doi.org/10.2174/1389450116666150416115547 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Serial Extraction Technique of Rich Antibacterial Compounds in <i>Sargassum
cristaefolium</i> Using Different Solvents and Testing their Activity
Current Bioactive Compounds AIDS-Defining Illnesses: A Comparison Between Before and After Commencement of Highly Active Antiretroviral Therapy (HAART)
Current HIV Research Novel Antiinflammatory and Antiinfective Agents
Anti-Infective Agents in Medicinal Chemistry 3-Phenyl-1H-Indole-5-Sulfonamides: Structure-Based Drug Design of a Promising Class of Carbonic Anhydrase Inhibitors
Current Pharmaceutical Design Cutaneous Adverse Drug Reactions Caused by Antituberculosis Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Nitroimidazole Radiopharmaceuticals in Bioimaging: Part I: Synthesis and Imaging Applications
Current Radiopharmaceuticals The Gut Microbiota in Inflammatory Bowel Disease
Current Pharmaceutical Design Atypical Presentation Of Anti-Retroviral Therapy Induced Lactic Acidosis as Acute Right Ventricular Failure And Severe Pulmonary Hypertension
New Emirates Medical Journal Recent Achievements in Understanding Immune Recovery of Children Treated with HAART
Current Pediatric Reviews Crosstalk Between The Immune Receptors and Gut Microbiota
Current Protein & Peptide Science Novel Therapies for Schizophrenia: Understanding the Glutamatergic Synapse and Potential Targets for Altering N-methyl-D-aspartate Neurotransmission
Recent Patents on CNS Drug Discovery (Discontinued) Tryptanthrin Analogues as Inhibitors of Enoyl-acyl Carrier Protein Reductase: Activity against Mycobacterium tuberculosis, Toxicity, Modeling of Enzyme Binding
Current Topics in Medicinal Chemistry Carbazole: A Potent Scaffold for Antitubercular Drugs
Mini-Reviews in Organic Chemistry Patent Selection
Recent Patents on Biotechnology Discovery of New Potential Antimalarial Compounds Using Virtual Screening of ZINC Database
Combinatorial Chemistry & High Throughput Screening QSAR Studies on NTF1836 Analogues as Mycothiol Biosynthesis Inhibitors
Letters in Drug Design & Discovery Antimycobacterial Activities of Oxazolidinones: A Review
Infectious Disorders - Drug Targets Nicotinamide Adenine Dinucleotide Based Therapeutics
Current Medicinal Chemistry Multi-Drug Resistant Pulmonary Tuberculosis
Current Respiratory Medicine Reviews Gold Nanoparticle-Mediated High-Performance Enzyme-Linked Immunosorbent Assay for Detection of Tuberculosis ESAT-6 Protein
Micro and Nanosystems